#BEGIN_DRUGCARD DB00563

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01BA01
L04AX03

# Absorption:
Generally well absorbed with a mean bioavailability of about 60%.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
Abitrexate
Antifolan
Arbitrexate
Emtexate
Folex
Ledertrexate
Metatrexan
Methotrate
Mexate
Rheumatrex
Trexall

# CAS_Registry_Number:
59-05-2

# ChEBI_ID:
6837

# Chemical_Formula:
C20H22N8O5

# Chemical_IUPAC_Name:
(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2244798

# Description:
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [PubChem]

# Dosage_Forms:
Solution	Intramuscular
Solution	Intrathecal
Solution	Intravenous
Tablet	Oral

# Drug_Category:
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Nucleic Acid Synthesis Inhibitors

# Drug_Interactions:
Acetylsalicylic acid	Acetylsalicylic acid increases the effect and toxicity of methotrexate.
Acitretin	Acitretin/etretinate increases the effect and toxicity of methotrexate
Amoxicillin	The penicillin increases the effect and toxicity of methotrexate
Ampicillin	The penicillin increases the effect and toxicity of methotrexate
Bacampicillin	The penicillin increases the effect and toxicity of methotrexate
Bismuth Subsalicylate	The salicylate, bismuth subsalicylate, increases the effect and toxicity of methotrexate.
Carbenicillin	The penicillin increases the effect and toxicity of methotrexate
Cholestyramine	Decreased levels of methotrexate
Ciprofloxacin	Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated.
Cisplatin	Cisplatin increases methotrexate toxicity
Clavulanate	The penicillin increases the effect and toxicity of methotrexate
Cloxacillin	The penicillin increases the effect and toxicity of methotrexate
Cyclosporine	Cyclosporine may increase the effect and toxicity of methotrexate.
Diclofenac	The NSAID, diclofenac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Dicloxacillin	The penicillin increases the effect and toxicity of methotrexate
Diflunisal	The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Digoxin	The antineoplasic agent decreases the effect of digoxin
Doxycycline	The tetracycline, doxycycline, may increase methotrexate toxicity.
Eltrombopag	Increases levels of Methotrexate via metabolism decrease. OATP transporter protein inhibition.
Ethotoin	The antineoplasic agent decreases the effect of hydantoin
Etodolac	The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Etretinate	Acitretin/etretinate increases the effect and toxicity of methotrexate
Fenoprofen	The NSAID, fenoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Flucloxacillin	The penicillin increases the effect and toxicity of methotrexate
Flurbiprofen	The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Fosphenytoin	The antineoplasic agent decreases the effect of hydantoin
Hydroxychloroquine	Hydroxychloroquine increases the effect and toxicity of methotrexate
Ibuprofen	The NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Indomethacin	The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Ketoprofen	The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Ketorolac	The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Magnesium salicylate	The salicylate, magnesium salicylate, increases the effect and toxicity of methotrexate.
Meclofenamic acid	The NSAID, meclofenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Mefenamic acid	The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Mephenytoin	The antineoplasic agent decreases the effect of hydantoin
Methicillin Acyl-Serine	The penicillin increases the effect and toxicity of methotrexate
Mezlocillin	The penicillin increases the effect and toxicity of methotrexate
Nabumetone	The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Nafcillin	The penicillin increases the effect and toxicity of methotrexate
Naproxen	The NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Omeprazole	Omeprazole increases the levels of methotrexate
Oxaprozin	The NSAID, oxaprozin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Penicillin G	The penicillin increases the effect and toxicity of methotrexate
Penicillin V	The penicillin increases the effect and toxicity of methotrexate
Phenylbutazone	The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Phenytoin	The antineoplasic agent decreases the effect of hydantoin
Piperacillin	The penicillin increases the effect and toxicity of methotrexate
Piroxicam	The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Pivampicillin	The penicillin increases the effect and toxicity of methotrexate
Probenecid	Probenecid increases the effect and toxicity of methotrexate
Procarbazine	Increased nephrotoxicity with this combination
Rilonacept	Rilonacept and methotrexate both increase immunosuppressive effects; combination may increase risk of myelosuppression.
Rofecoxib	Rofecoxib increases the levels of methotrexate
Salicylate-sodium	The salicylate, salicylate-sodium, increases the effect and toxicity of methotrexate.
Salsalate	The salicylate, salsalate, increases the effect and toxicity of methotrexate.
Sulfacytine	The sulfamide increases the toxicity of methotrexate
Sulfadiazine	The sulfamide increases the toxicity of methotrexate
Sulfadimethoxine	The sulfamide increases the toxicity of methotrexate
Sulfadoxine	The sulfamide increases the toxicity of methotrexate
Sulfamerazine	The sulfamide increases the toxicity of methotrexate
Sulfamethazine	The sulfamide increases the toxicity of methotrexate
Sulfamethizole	The sulfamide increases the toxicity of methotrexate
Sulfamethoxazole	The sulfamide increases the toxicity of methotrexate
Sulfapyridine	The sulfamide increases the toxicity of methotrexate
Sulfathiazole	The sulfamide increases the toxicity of methotrexate
Sulfisoxazole	The sulfamide increases the toxicity of methotrexate
Sulindac	The NSAID, sulindac, may decrease the clearance methotrexate. Consider alternate therapy, especially in patients receiving high antineoplastic doses of methotrexate. Otherwise, monitor for hematologic and renal toxicities.
Tenoxicam	Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.
Tetracycline	Tetracycline may increase methotrexate toxicity.
Tiaprofenic acid	Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.
Ticarcillin	The penicillin increases the effect and toxicity of methotrexate
Tolmetin	Tolmetin may decrease the renal excretion of Methotrexate. Alternate therapy should be considered. Otherwise, monitor for hemotologic and renal toxicities.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trimethoprim	Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity.
Trisalicylate-choline	The salicylate, trisalicylate-choline, increases the effect and toxicity of methotrexate.

# Drug_Reference:
15001324	Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81.
15639649	Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-5.92

# Experimental_LogP_Hydrophobicity:
-1.85

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2600 mg/L

# Food_Interactions:
Milk appears to reduce its absorption.
Take without regard to meals. Limit caffeine intake.

# GenBank_ID:
Not Available

# Generic_Name:
Methotrexate

# HET_ID:
MTX

# Half_Life:
Low doses: 3 to 10 hours; High doses: 8 to 15 hours.

# InChI_Identifier:
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

# InChI_Key:
InChIKey=FBOZXECLQNJBKD-ZDUSSCGKSA-N

# Indication:
For the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Also for the treatment of severe psoriasis and severe, active, classical or definite rheumatoid arthritis.

# KEGG_Compound_ID:
C01937

# KEGG_Drug_ID:
D00142

# LIMS_Drug_ID:
563

# Mechanism_Of_Action:
Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.

# Melting_Point:
195 Â°C

# Molecular_Weight_Avg:
454.4393

# Molecular_Weight_Mono:
454.171315854

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1MVT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/met1257.shtml

# Pathways:
Methotrexate Pathway	SMP00432

# PharmGKB_ID:
PA450428

# Pharmacology:
Methotrexate is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Methotrexate inhibits folic acid reductase which is responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon transfer reactions occur which require specific coenzymes synthesized in the cell from tetrahydrofolic acid. Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme, folic acid reductase. Methotrexate looks a lot like folic acid to the enzyme, so it binds to it quite strongly and inhibits the enzyme. Thus, DNA synthesis cannot proceed because the coenzymes needed for one-carbon transfer reactions are not produced from tetrahydrofolic acid because there is no tetrahydrofolic acid. Methotrexate selectively affects the most rapidly dividing cells (neoplastic and psoriatic cells). Methotrexate is also indicated in the management of severe, active, classical, or definite rheumatoid arthritis.

# Predicted_LogP_Hydrophobicity:
-0.91

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.71e-01 g/l

# Primary_Accession_No:
DB00563

# Protein_Binding:
50%, primarily to albumin

# PubChem_Compound_ID:
126941

# PubChem_Substance_ID:
46507678

# RxList_Link:
http://www.rxlist.com/cgi/generic/mtx.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00353

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Amethopterin
Amethopterine
HDMTX
L-Amethopterin
MTX
Methopterin
Methotextrate
Methotrexat
Methotrexate Sodium
Methylaminopterin
Methylaminopterinum
N-Bismethylpteroylglutamic Acid

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include bone marrow suppression and gastrointestinal toxicity. LD<sub>50</sub>=43mg/kg(orally in rat).

# Update_Date:
2013-02-08 16:19:27 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Methotrexate

# pKa_Isoelectric_Point:
4.7

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
GGH

# Phase_1_Metabolizing_Enzyme_1_ID:
293

# Phase_1_Metabolizing_Enzyme_1_Name:
Gamma-glutamyl hydrolase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Gamma-glutamyl hydrolase precursor
MASPGCLLCVLGLLLCGAASLELSRPHGDTAKKPIIGILMQKCRNKVMKNYGRYYIAASY
VKYLESAGARVVPVRLDLTEKDYEILFKSINGILFPGGSVDLRRSDYAKVAKIFYNLSIQ
SFDDGDYFPVWGTCLGFEELSLLISGECLLTATDTVDVAMPLNFTGGQLHSRMFQNFPTE
LLLSLAVEPLTANFHKWSLSVKNFTMNEKLKKFFNVLTTNTDGKIEFISTMEGYKYPVYG
VQWHPEKAPYEWKNLDGISHAPNAVKTAFYLAEFFVNEARKNNHHFKSESEEEKALIYQF
SPIYTGNISSFQQCYIFD

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
Q92820

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
TYMS

# Phase_1_Metabolizing_Enzyme_2_ID:
359

# Phase_1_Metabolizing_Enzyme_2_Name:
Thymidylate synthase

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Thymidylate synthase
PVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGM
QARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSL
GFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCA
WNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHIT
GLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGY
NPHPTIKMEMAV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P04818

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
DHFR

# Phase_1_Metabolizing_Enzyme_3_ID:
365

# Phase_1_Metabolizing_Enzyme_3_Name:
Dihydrofolate reductase

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Dihydrofolate reductase
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P00374

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
FPGS

# Phase_1_Metabolizing_Enzyme_4_ID:
773

# Phase_1_Metabolizing_Enzyme_4_Name:
Folylpolyglutamate synthase, mitochondrial

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Folylpolyglutamate synthase, mitochondrial precursor
MSRARSHLRAALFLAAASARGITTQVAARRGLSAWPVPQEPSMEYQDAVRMLNTLQTNAG
YLEQVKRQRGDPQTQLEAMELYLARSGLQVEDLDRLNIIHVTGTKGKGSTCAFTECILRS
YGLKTGFFSSPHLVQVRERIRINGQPISPELFTKYFWRLYHRLEETKDGSCVSMPPYFRF
LTLMAFHVFLQEKVDLAVVEVGIGGAYDCTNIIRKPVVCGVSSLGIDHTSLLGDTVEKIA
WQKGGIFKQGVPAFTVLQPEGPLAVLRDRAQQISCPLYLCPMLEALEEGGPPLTLGLEGE
HQRSNAALALQLAHCWLQRQDRHGAGEPKASRPGLLWQLPLAPVFQPTSHMRLGLRNTEW
PGRTQVLRRGPLTWYLDGAHTASSAQACVRWFRQALQGRERPSGGPEVRVLLFNATGDRD
PAALLKLLQPCQFDYAVFCPNLTEVSSTGNADQQNFTVTLDQVLLRCLEHQQHWNHLDEE
QASPDLWSAPSPEPGGSASLLLAPHPPHTCSASSLVFSCISHALQWISQGRDPIFQPPSP
PKGLLTHPVAHSGASILREAAAIHVLVTGSLHLVGGVLKLLEPALSQ

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
Q05932

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
ATIC

# Phase_1_Metabolizing_Enzyme_5_ID:
2287

# Phase_1_Metabolizing_Enzyme_5_Name:
Bifunctional purine biosynthesis protein PURH [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Bifunctional purine biosynthesis protein PURH [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase
MAPGQLALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEM
LGGRVKTLHPAVHAGILARNIPEDNADMARLDFNLIRVVACNLYPFVKTVASPGVTVEEA
VEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQLALKAFT
HTAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVLNGAPGFINL
CDALNAWQLVKELKEALGIPAAASFKHVSPAGAAVGIPLSEDEAKVCMVYDLYKTLTPIS
AAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIIAPGYEEEALTILSKKKNG
NYCVLQMDQSYKPDENEVRTLFGLHLSQKRNNGVVDKSLFSNVVTKNKDLPESALRDLIV
ATIAVKYTQSNSVCYAKNGQVIGIGAGQQSRIHCTRLAGDKANYWWLRHHPQVLSMKFKT
GVKRAEISNAIDQYVTGTIGEDEDLIKWKALFEEVPELLTEAEKKEWVEKLTEVSISSDA
FFPFRDNVDRAKRSGVAYIAAPSGSAADKVVIEACDELGIILAHTNLRLFHH

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P31939

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
MTHFR

# Phase_1_Metabolizing_Enzyme_6_ID:
3917

# Phase_1_Metabolizing_Enzyme_6_Name:
Methylenetetrahydrofolate reductase

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Methylenetetrahydrofolate reductase
MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWF
SLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYC
GLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVK
HIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFV
KACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIE
LAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREE
DVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKM
WGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGIL
TINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHL
VNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYE
EESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P42898

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
AOX1

# Phase_1_Metabolizing_Enzyme_7_ID:
6020

# Phase_1_Metabolizing_Enzyme_7_Name:
Aldehyde oxidase

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Aldehyde oxidase
MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYN
PITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPG
MVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCC
LDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSER
MMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHA
YNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHII
SRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSR
KWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKL
IGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPV
HYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYC
DDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAE
KFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPE
RKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKY
IQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGE
DMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKF
PNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEID
QTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGS
RAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETV
PNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVG
YFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAID
IGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSN
TLYSSKGLGESGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFT
KMIPRDEPGSYVPWNVPI

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
Q06278

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
PGD

# Phase_1_Metabolizing_Enzyme_8_ID:
6040

# Phase_1_Metabolizing_Enzyme_8_Name:
6-phosphogluconate dehydrogenase, decarboxylating

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>6-phosphogluconate dehydrogenase, decarboxylating
MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEAKGTKVVGAQSLKE
MVSKLKKPRRIILLVKAGQAVDDFIEKLVPLLDTGDIIIDGGNSEYRDTTRRCRDLKAKG
ILFVGSGVSGGEEGARYGPSLMPGGNKEAWPHIKTIFQGIAAKVGTGEPCCDWVGDEGAG
HFVKMVHNGIEYGDMQLICEAYHLMKDVLGMAQDEMAQAFEDWNKTELDSFLIEITANIL
KFQDTDGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLKDERIQA
SKKLKGPQKFQFDGDKKSFLEDIRKALYASKIISYAQGFMLLRQAATEFGWTLNYGGIAL
MWRGGCIIRSVFLGKIKDAFDRNPELQNLLLDDFFKSAVENCQDSWRRAVSTGVQAGIPM
PCFTTALSFYDGYRHEMLPASLIQAQRDYFGAHTYELLAKPGQFIHTNWTGHGGTVSSSS
YNA

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P52209

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16647263	Totani K, Matsuo I, Ihara Y, Ito Y: High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates. Bioorg Med Chem. 2006 Aug 1;14(15):5220-9. Epub 2006 May 2.
16936229	Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H: A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006 Nov;70(5):1832-9. Epub 2006 Aug 25.
16971132	Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12.
17130456	Bennett B, Langan P, Coates L, Mustyakimov M, Schoenborn B, Howell EE, Dealwis C: Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18493-8. Epub 2006 Nov 27.
17333344	Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153-81.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
DHFR

# Drug_Target_1_GenBank_ID_Gene:
J00140

# Drug_Target_1_GenBank_ID_Protein:
182724

# Drug_Target_1_GeneCard_ID:
DHFR

# Drug_Target_1_Gene_Name:
DHFR

# Drug_Target_1_Gene_Sequence:
>564 bp
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1731871	Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH: Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution. Biochemistry. 1992 Jan 14;31(1):218-29.
2248959	Davies JF 2nd, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J: Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry. 1990 Oct 9;29(40):9467-79.
3383852	Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate. Eur J Biochem. 1988 Jun 1;174(2):377-85.
6235374	Yang JK, Masters JN, Attardi G: Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes. J Mol Biol. 1984 Jun 25;176(2):169-87.
6323448	Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW: The functional human dihydrofolate reductase gene. J Biol Chem. 1984 Mar 25;259(6):3933-43.
6687716	Masters JN, Attardi G: The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase. Gene. 1983 Jan-Feb;21(1-2):59-63.
9374868	Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL: Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903.

# Drug_Target_1_HGNC_ID:
HGNC:2861

# Drug_Target_1_HPRD_ID:
00519

# Drug_Target_1_ID:
365

# Drug_Target_1_Locus:
5q11.2-q13.2

# Drug_Target_1_Molecular_Weight:
21322

# Drug_Target_1_Name:
Dihydrofolate reductase

# Drug_Target_1_Number_of_Residues:
186

# Drug_Target_1_PDB_ID:
1MVT

# Drug_Target_1_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_1_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_1_Protein_Sequence:
>Dihydrofolate reductase
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND

# Drug_Target_1_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P00374

# Drug_Target_1_SwissProt_Name:
DYR_HUMAN

# Drug_Target_1_Synonyms:
EC 1.5.1.3

# Drug_Target_1_Theoretical_pI:
7.60

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00563
